Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1981 Dec;40(6):564–566. doi: 10.1136/ard.40.6.564

Corneal chrysiasis and clinical improvement with chrysotherapy in rheumatoid arthritis

P J Prouse 1, J J Kanski 1, J M Gumpel 1
PMCID: PMC1000831  PMID: 6800311

Abstract

The deposition of gold in the cornea—ocular chrysiasis—is a normal event during chrysotherapy. It may reflect tissue deposition of gold and be of value in predicting clinical improvement or toxic reactions. We studied 21 patients with rheumatoid arthritis on chrysotherapy but could find no relationship between the appearance of ocular chrysiasis, clinical improvement, and toxicity.

Full text

PDF
564

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bron A. J. Vortex patterns of the corneal epithelium. Trans Ophthalmol Soc U K. 1973;93(0):455–472. [PubMed] [Google Scholar]
  2. Davis P., Hughes G. R. Significance of eosinophilia during gold therapy. Arthritis Rheum. 1974 Nov-Dec;17(6):964–968. doi: 10.1002/art.1780170607. [DOI] [PubMed] [Google Scholar]
  3. Gottlieb N. L., Major J. C. Ocular chrysiasis correlated with gold concentrations in the crystalline lens during chrysotherapy. Arthritis Rheum. 1978 Jul-Aug;21(6):704–708. doi: 10.1002/art.1780210616. [DOI] [PubMed] [Google Scholar]
  4. Gottlieb N. L., Smith P. M., Penneys N. S., Smith E. M. Gold concentrations in hair, nail, and skin during chrysotherapy. Arthritis Rheum. 1974 Jan-Feb;17(1):56–62. doi: 10.1002/art.1780170109. [DOI] [PubMed] [Google Scholar]
  5. Gumpel J. M. Cyclophosphamide, gold and penicillamine--disease-modifying drugs in rheumatoid arthritis--tailored dosage and ultimate success. Rheumatol Rehabil. 1976 Aug;15(3):217–220. doi: 10.1093/rheumatology/15.3.217. [DOI] [PubMed] [Google Scholar]
  6. Hashimoto A., Maeda Y., Ito H., Okazaki M., Hara T. Corneal chrysiasis. A clinical study in rheumatoid arthritis patients receiving gold therapy. Arthritis Rheum. 1972 May-Jun;15(3):309–315. doi: 10.1002/art.1780150313. [DOI] [PubMed] [Google Scholar]
  7. Huskisson E. C., Gibson T. J., Balme H. W., Berry H., Burry H. C., Grahame R., Hart F. D., Henderson D. R., Wojtulewski J. A. Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report. Ann Rheum Dis. 1974 Nov;33(6):532–535. doi: 10.1136/ard.33.6.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kay A. G. Myelotoxicity of gold. Br Med J. 1976 May 22;1(6020):1266–1268. doi: 10.1136/bmj.1.6020.1266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Penneys N. S., Kramer K., Gottlieb N. L. The quantitative distribution of gold in skin during chrysotherapy. J Invest Dermatol. 1975 Sep;65(3):331–333. doi: 10.1111/1523-1747.ep12598396. [DOI] [PubMed] [Google Scholar]
  10. ROBERTS W. H., WOLTER J. R. Ocular chrysiasis. AMA Arch Ophthalmol. 1956 Jul;56(1):48–52. doi: 10.1001/archopht.1956.00930040052007. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES